Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial.

Notably, the P value for interaction was nearly significant ( P = .054) between subgroups of patients who had received previous hormonal therapy (HR, 0.45 [95% CI, 0.31 to 0.65]) and those who had not received previous hormonal therapy (HR, 0.79 [95% CI, 0.51 to 1.23]).

also in 3,349 other papers